Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 30 versus ADDERALL XR 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 30 versus ADDERALL XR 25.
ADDERALL 30 vs ADDERALL XR 25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Adderall XR is a combination of dextroamphetamine and amphetamine, which are non-catecholamine sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals and inhibit their reuptake, resulting in increased synaptic concentrations. This leads to CNS stimulation.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
20-60 mg orally once daily in the morning; starting dose 20 mg, titrate weekly by 10-20 mg based on response and tolerability.
None Documented
None Documented
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Dextroamphetamine: 10-13 hours; levoamphetamine: 11-14 hours. Effective half-life supports once-daily dosing with extended duration.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
Renal: approximately 90% (30-40% unchanged, remainder as metabolites); fecal: minimal (<2%) via biliary elimination.
Category C
Category C
CNS Stimulant
CNS Stimulant